Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Open Label, Non-randomized Study of Second or Third Line Treatment With Sorafenib (BAY 43-9006) in Patients Affected by Relapsed High-grade Osteosarcoma.

NCT00889057 is registered in ClinicalTrials.gov with Italian Sarcoma Group as lead sponsor.

NCT NCT00889057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00889057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Open Label, Non-randomized Study of Second or Third Line Treatment With Sorafenib (BAY 43-9006) in Patients Affected by Relapsed High-grade Osteosarcoma.
Lead sponsor
Italian Sarcoma Group
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2008
Completion date
June 30, 2011
Enrollment
35 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

osteosarcoma